<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974687</url>
  </required_header>
  <id_info>
    <org_study_id>3682-001</org_study_id>
    <secondary_id>U1111-1149-5611</secondary_id>
    <secondary_id>IDX-04B-001</secondary_id>
    <secondary_id>2013-004043-23</secondary_id>
    <secondary_id>MK-3682-001</secondary_id>
    <nct_id>NCT01974687</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)</brief_title>
  <official_title>A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-part study to evaluate the safety, tolerability, and pharmacokinetics (PK) of
      uprifosbuvir (MK-3682/IDX21437) in healthy participants and in participants infected with
      Hepatitis C virus (HCV) genotype (GT)1-GT6. The effect of food on the PK of uprifosbuvir will
      be evaluated. The antiviral activity of uprifosbuvir will also be assessed in HCV-infected
      participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2013</start_date>
  <completion_date type="Actual">September 11, 2015</completion_date>
  <primary_completion_date type="Actual">September 2, 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (AE)</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered study drug, and that does not necessarily have a causal relationship with the study drug(s). An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug(s), whether or not related to study drug(s). The percentage of participants who experienced at least one AE is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Treatment-emergent Serious AE (SAE)</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>An SAE was defined as any untoward medical occurrence that at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. The percentage of participants who experienced at least one SAE is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced a Treatment-emergent Dose-limiting Toxicity (DLT)</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>A DLT was defined as any of the following events: Any SAE considered by the investigator to be at least reasonably or possibly related to study drug; Any Grade 3 clinical AE considered by the investigator to be at least reasonably or possibly related to study drug; Any Grade 3 confirmed laboratory abnormalities considered by the investigator to be at least reasonably or possibly related to study drug, except for asymptomatic Grade ¾ cholesterol and triglyceride; Any clinical or laboratory AE of any intensity that is considered by the investigator to be at least reasonably or possibly related to study drug that necessitates permanent discontinuation of study drug; Confirmed increase in QT interval corrected for heart rate using Fridericia's (QTcF) formula ≥60 msec over Baseline or an absolute QTcF ≥500 msec.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Treatment-emergent Grade 1, 2, 3, 4 or 5 Laboratory Abnormality</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Laboratory abnormalities were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Treatment-emergent AEs (TEAEs)were graded as: Grade 1: Mild TEAE as Worst Severity; Grade 2: Moderate TEAE as Worst Severity; Grade 3: Severe TEAE as Worst Severity; Grade 4: Potentially Life-Threatening TEAE as Worst Severity; Grade 5: TEAE Leading to Death. The percentage of participants who experienced at least one Grade 1, 2, 3, 4 or 5 laboratory abnormality is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Drug Due to a Treatment-emergent AE</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>The percentage of participants who discontinued study drug due to an AE is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Drug Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum (Peak) Observed Plasma Drug Concentration (Cmax) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir After Singe Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, With Itraconazole (Group F)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Terminal Half-Life (t1/2) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, With Itraconazole (Group F)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity for M6, a metabolite of uprifosbuvir, estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Maximum observed plasma drug concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1,HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Time to maximum plasma concentration was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</measure>
    <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Urine Excretion of Unchanged Uprifosbuvir in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Cumulative urine excretion of unchanged MK-3682 in healthy participants was obtained. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Urine Excretion of Unchanged M6 in Healthy Participants (Group A)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
    <description>Cumulative urine excretion of unchanged M6 in healthy participants was obtained. All participants were fasted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in HCV RNA From Baseline on Day 8 Following Uprifosbuvir 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</measure>
    <time_frame>Baseline and Day 8</time_frame>
    <description>Reduction in HCV RNA from baseline on Day 8 following uprifosbuvir 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-infected participants was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Reduction in log10 HCV RNA From Baseline - Normal Participants (From Groups B and C) vs. Mild Hepatic Impairment Participants (Group E)</measure>
    <time_frame>Baseline and 28 days after last dose of study drug (Up to 42 days)</time_frame>
    <description>Reduction in HCV RNA from baseline on Day 8 following uprifosbuvir 50-450 mg for 7 Days in Genotype (Gt) 1, HCV-infected participants was obtained.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A: Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will receive sequentially higher doses of uprifosbuvir (10 mg - 300 mg) capsules or matching placebo capsules once daily (QD) on Day 1 (Cohorts 1a-3a, 5a), Days 1 and 7 (Cohort 4a), or Day 1 - Day 7 (Cohort 6a). Dosing of next cohort will be based on review of available safety and PK data. Dosing will occur under fasted conditions with the exception of Cohort 4a, in which drug administration will occur under both fasted and fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: GT1 HCV-infected, treatment naive on Day 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1 participants with no prior direct-acting antiviral (DAA) exposure will receive a single dose of uprifosbuvir (10 mg - 300 mg) for 1 day across sequential dose cohorts. Dosing will commence following review of available safety and PK data from respective dose cohorts in Group A. All dosing will occur under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: GT1 HCV-infected on Days 1-7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1 participants will receive uprifosbuvir (50 mg - 400 mg in capsules or 300 mg or 450 mg in tablets) or matching placebo capsules QD for 7 days. Dosing will commence following review of available safety and PK data of Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: GT2 through GT6 HCV-infected on Days 1-7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT2 - GT6 participants will receive uprifosbuvir (50 mg - 300 mg) capsules QD for 7 days. Dosing will commence following review of available safety and PK data from Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E: GT1 HCV-infected on Days 1-7, mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1 participants with mildly impaired hepatic function will receive uprifosbuvir (150 mg - 450 mg) capsules QD for 1 or 7 days. Dosing of subsequent cohorts will be based on review of available safety and PK data. Fed vs. fasted dosing will be dependent on food effect results from Group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F: GT1 HCV-infected on Days 1-7, + Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV GT1 participants will receive itraconazole 200 mg twice daily (BID) on Day -5 and itraconazole 200 mg QD from Day -4 to Day 11. Participants will also be co-administered uprifosbuvir 300 mg from Day 1 to Day 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uprifosbuvir</intervention_name>
    <description>Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.</description>
    <arm_group_label>Group A: Healthy</arm_group_label>
    <arm_group_label>Group B: GT1 HCV-infected, treatment naive on Day 1</arm_group_label>
    <arm_group_label>Group C: GT1 HCV-infected on Days 1-7</arm_group_label>
    <arm_group_label>Group D: GT2 through GT6 HCV-infected on Days 1-7</arm_group_label>
    <arm_group_label>Group E: GT1 HCV-infected on Days 1-7, mild hepatic impairment</arm_group_label>
    <other_name>MK-3682/IDX21437</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to uprifosbuvir capsule administered by mouth.</description>
    <arm_group_label>Group A: Healthy</arm_group_label>
    <arm_group_label>Group C: GT1 HCV-infected on Days 1-7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.</description>
    <arm_group_label>Group F: GT1 HCV-infected on Days 1-7, + Itraconazole</arm_group_label>
    <other_name>Sporanox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Participants:

          -  of childbearing potential must have agreed to use a double method of birth control
             (one of which must be a barrier) from Screening through at least 90 days after the
             last dose of the study drug

          -  must not have consumed grapefruit or grapefruit juice within 7 days of Day -1 and
             throughout the study

        HCV Participants:

          -  documented clinical history compatible with chronic hepatitis C.

          -  have not received direct-acting antiviral treatment for hepatitis C infection

          -  has HCV Genotype 1, 2, 3, 4, 5 or 6

        Exclusion Criteria:

        All Participants:

          -  pregnant or breastfeeding

          -  co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).

          -  decompensated liver disease

          -  other clinically significant medical conditions or laboratory abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <results_first_submitted>December 4, 2017</results_first_submitted>
  <results_first_submitted_qc>September 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2018</results_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C virus</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Uprifosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Per protocol, the Group D part of the study allowed to randomize Genotype 2, 3, 4, 5 and 6 Hepatitis C Virus (HCV)-infected participants, however, only Genotype 2 and 3 HCV-infected participants were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
          <description>Participants were administered a single dose of uprifosbuvir (MK-3682/IDX21437) 10 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P2">
          <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P3">
          <title>Group A: Uprifosbuvir 150 mg (Cohort 4a)</title>
          <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
        </group>
        <group group_id="P4">
          <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P5">
          <title>Group A: Placebo (Cohort 6a)</title>
          <description>Participants were administered single doses of uprifosbuvir-matching placebo oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P6">
          <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P7">
          <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P8">
          <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P9">
          <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P10">
          <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P11">
          <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P12">
          <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P13">
          <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P14">
          <title>Groups C &amp; D: Uprifosbuvir 250 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 250 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P15">
          <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P16">
          <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P17">
          <title>Groups C &amp; D: Uprifosbuvir 300 mg (Tablet)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P18">
          <title>Groups C &amp; D: Uprifosbuvir 450 mg (Tablet)</title>
          <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P19">
          <title>Groups C &amp; D: Placebo (Pooled)</title>
          <description>Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P20">
          <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
          <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P21">
          <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P22">
          <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
          <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="P23">
          <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
        </group>
        <group group_id="P24">
          <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="P25">
          <title>Group A: Placebo (Cohorts 1a-5a - Pooled)</title>
          <description>Participants were administered a single dose of uprifosbuvir-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="13"/>
                <participants group_id="P13" count="13"/>
                <participants group_id="P14" count="10"/>
                <participants group_id="P15" count="19"/>
                <participants group_id="P16" count="9"/>
                <participants group_id="P17" count="9"/>
                <participants group_id="P18" count="11"/>
                <participants group_id="P19" count="9"/>
                <participants group_id="P20" count="3"/>
                <participants group_id="P21" count="3"/>
                <participants group_id="P22" count="8"/>
                <participants group_id="P23" count="8"/>
                <participants group_id="P24" count="6"/>
                <participants group_id="P25" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="11">2 participants discontinued prior to receiving study drug</participants>
                <participants group_id="P13" count="10">3 participants discontinued prior to receiving study drug</participants>
                <participants group_id="P14" count="8">2 participants discontinued prior to receiving study drug</participants>
                <participants group_id="P15" count="18">1 participant discontinued prior to receiving study drug</participants>
                <participants group_id="P16" count="8">1 participant discontinued prior to receiving study drug</participants>
                <participants group_id="P17" count="8">1 participant discontinued prior to receiving study drug</participants>
                <participants group_id="P18" count="8">3 participants discontinued prior to receiving study drug</participants>
                <participants group_id="P19" count="9"/>
                <participants group_id="P20" count="3"/>
                <participants group_id="P21" count="3"/>
                <participants group_id="P22" count="8"/>
                <participants group_id="P23" count="8"/>
                <participants group_id="P24" count="6"/>
                <participants group_id="P25" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="11"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="8"/>
                <participants group_id="P15" count="18"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="9"/>
                <participants group_id="P20" count="3"/>
                <participants group_id="P21" count="3"/>
                <participants group_id="P22" count="8"/>
                <participants group_id="P23" count="8"/>
                <participants group_id="P24" count="6"/>
                <participants group_id="P25" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="3"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population consisted of all participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A: Placebo (Cohort 1a-Cohort 5a - Pooled)</title>
          <description>Participants were administered a single dose of uprifosbuvir-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).</description>
        </group>
        <group group_id="B2">
          <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B3">
          <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B4">
          <title>Group A: Uprifosbuvir 150 mg (Cohort 4a)</title>
          <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
        </group>
        <group group_id="B5">
          <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B6">
          <title>Group A: Placebo (Cohort 6a)</title>
          <description>Participants were administered single doses of uprifosbuvir-matching placebo oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B7">
          <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B8">
          <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B9">
          <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B10">
          <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B11">
          <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B12">
          <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B13">
          <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B14">
          <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B15">
          <title>Groups C &amp; D: Uprifosbuvir 250 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 250 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B16">
          <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B17">
          <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B18">
          <title>Groups C &amp; D: Uprifosbuvir 300 mg (Tablet)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B19">
          <title>Groups C &amp; D: Uprifosbuvir 450 mg (Tablet)</title>
          <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B20">
          <title>Groups C &amp; D: Placebo (Pooled)</title>
          <description>Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B21">
          <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
          <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B22">
          <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B23">
          <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
          <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="B24">
          <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
        </group>
        <group group_id="B25">
          <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="B26">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="3"/>
            <count group_id="B11" value="3"/>
            <count group_id="B12" value="3"/>
            <count group_id="B13" value="11"/>
            <count group_id="B14" value="10"/>
            <count group_id="B15" value="8"/>
            <count group_id="B16" value="18"/>
            <count group_id="B17" value="8"/>
            <count group_id="B18" value="8"/>
            <count group_id="B19" value="8"/>
            <count group_id="B20" value="9"/>
            <count group_id="B21" value="3"/>
            <count group_id="B22" value="3"/>
            <count group_id="B23" value="8"/>
            <count group_id="B24" value="8"/>
            <count group_id="B25" value="6"/>
            <count group_id="B26" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="11"/>
                    <measurement group_id="B14" value="10"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="18"/>
                    <measurement group_id="B17" value="8"/>
                    <measurement group_id="B18" value="8"/>
                    <measurement group_id="B19" value="8"/>
                    <measurement group_id="B20" value="9"/>
                    <measurement group_id="B21" value="3"/>
                    <measurement group_id="B22" value="3"/>
                    <measurement group_id="B23" value="8"/>
                    <measurement group_id="B24" value="8"/>
                    <measurement group_id="B25" value="6"/>
                    <measurement group_id="B26" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="7.72"/>
                    <measurement group_id="B2" value="29.2" spread="7.36"/>
                    <measurement group_id="B3" value="33.3" spread="15.06"/>
                    <measurement group_id="B4" value="35.5" spread="11.76"/>
                    <measurement group_id="B5" value="35.2" spread="9.87"/>
                    <measurement group_id="B6" value="36.0" spread="2.83"/>
                    <measurement group_id="B7" value="35.3" spread="12.69"/>
                    <measurement group_id="B8" value="37.0" spread="9.54"/>
                    <measurement group_id="B9" value="42.3" spread="7.23"/>
                    <measurement group_id="B10" value="46.7" spread="4.16"/>
                    <measurement group_id="B11" value="43.3" spread="5.69"/>
                    <measurement group_id="B12" value="41.3" spread="8.96"/>
                    <measurement group_id="B13" value="41.2" spread="10.68"/>
                    <measurement group_id="B14" value="42.7" spread="10.37"/>
                    <measurement group_id="B15" value="44.3" spread="8.63"/>
                    <measurement group_id="B16" value="40.1" spread="11.69"/>
                    <measurement group_id="B17" value="43.3" spread="8.45"/>
                    <measurement group_id="B18" value="40.5" spread="11.70"/>
                    <measurement group_id="B19" value="40.5" spread="8.94"/>
                    <measurement group_id="B20" value="43.7" spread="7.68"/>
                    <measurement group_id="B21" value="57.0" spread="4.36"/>
                    <measurement group_id="B22" value="56.3" spread="3.06"/>
                    <measurement group_id="B23" value="49.1" spread="8.04"/>
                    <measurement group_id="B24" value="43.1" spread="12.54"/>
                    <measurement group_id="B25" value="31.3" spread="11.60"/>
                    <measurement group_id="B26" value="40.47" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="4"/>
                    <measurement group_id="B20" value="3"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="6"/>
                    <measurement group_id="B25" value="3"/>
                    <measurement group_id="B26" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="10"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="13"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="4"/>
                    <measurement group_id="B20" value="6"/>
                    <measurement group_id="B21" value="3"/>
                    <measurement group_id="B22" value="3"/>
                    <measurement group_id="B23" value="7"/>
                    <measurement group_id="B24" value="2"/>
                    <measurement group_id="B25" value="3"/>
                    <measurement group_id="B26" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (AE)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered study drug, and that does not necessarily have a causal relationship with the study drug(s). An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug(s), whether or not related to study drug(s). The percentage of participants who experienced at least one AE is presented.</description>
        <time_frame>Up to 42 days</time_frame>
        <population>Safety Population: all participants who received at least one dose of the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Placebo (Cohort 1a-Cohort 5a - Pooled)</title>
            <description>Participants were administered a single dose of uprifosbuvir-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a) (Fasted and Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O6">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Group A: Placebo (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O13">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O14">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O15">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O16">
            <title>Groups C &amp; D: Uprifosbuvir 250 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 250 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O17">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O18">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O19">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O20">
            <title>Groups C &amp; D: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O21">
            <title>Groups C &amp; D: Placebo (Pooled)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O22">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O23">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O24">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O25">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (AE)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered study drug, and that does not necessarily have a causal relationship with the study drug(s). An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug(s), whether or not related to study drug(s). The percentage of participants who experienced at least one AE is presented.</description>
          <population>Safety Population: all participants who received at least one dose of the study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="10"/>
                <count group_id="O16" value="8"/>
                <count group_id="O17" value="18"/>
                <count group_id="O18" value="8"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="8"/>
                <count group_id="O21" value="9"/>
                <count group_id="O22" value="3"/>
                <count group_id="O23" value="3"/>
                <count group_id="O24" value="8"/>
                <count group_id="O25" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="33.3"/>
                    <measurement group_id="O10" value="66.7"/>
                    <measurement group_id="O11" value="33.3"/>
                    <measurement group_id="O12" value="66.7"/>
                    <measurement group_id="O13" value="66.7"/>
                    <measurement group_id="O14" value="72.7"/>
                    <measurement group_id="O15" value="70.0"/>
                    <measurement group_id="O16" value="87.5"/>
                    <measurement group_id="O17" value="44.4"/>
                    <measurement group_id="O18" value="62.5"/>
                    <measurement group_id="O19" value="75.0"/>
                    <measurement group_id="O20" value="62.5"/>
                    <measurement group_id="O21" value="66.7"/>
                    <measurement group_id="O22" value="0.0"/>
                    <measurement group_id="O23" value="100.0"/>
                    <measurement group_id="O24" value="62.5"/>
                    <measurement group_id="O25" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least One Treatment-emergent Serious AE (SAE)</title>
        <description>An SAE was defined as any untoward medical occurrence that at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. The percentage of participants who experienced at least one SAE is presented.</description>
        <time_frame>Up to 42 days</time_frame>
        <population>Safety Population: all participants who received at least one dose of the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Placebo (Cohort 1a-Cohort 5a - Pooled)</title>
            <description>Participants were administered a single dose of uprifosbuvir-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a) (Fasted and Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O6">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Group A: Placebo (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O13">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O14">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O15">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O16">
            <title>Groups C &amp; D: Uprifosbuvir 250 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 250 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O17">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O18">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O19">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O20">
            <title>Groups C &amp; D: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O21">
            <title>Groups C &amp; D: Placebo (Pooled)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O22">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O23">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O24">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O25">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least One Treatment-emergent Serious AE (SAE)</title>
          <description>An SAE was defined as any untoward medical occurrence that at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. The percentage of participants who experienced at least one SAE is presented.</description>
          <population>Safety Population: all participants who received at least one dose of the study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="10"/>
                <count group_id="O16" value="8"/>
                <count group_id="O17" value="18"/>
                <count group_id="O18" value="8"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="8"/>
                <count group_id="O21" value="9"/>
                <count group_id="O22" value="3"/>
                <count group_id="O23" value="3"/>
                <count group_id="O24" value="8"/>
                <count group_id="O25" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="0.0"/>
                    <measurement group_id="O14" value="0.0"/>
                    <measurement group_id="O15" value="0.0"/>
                    <measurement group_id="O16" value="0.0"/>
                    <measurement group_id="O17" value="0.0"/>
                    <measurement group_id="O18" value="0.0"/>
                    <measurement group_id="O19" value="0.0"/>
                    <measurement group_id="O20" value="0.0"/>
                    <measurement group_id="O21" value="0.0"/>
                    <measurement group_id="O22" value="0.0"/>
                    <measurement group_id="O23" value="0.0"/>
                    <measurement group_id="O24" value="0.0"/>
                    <measurement group_id="O25" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced a Treatment-emergent Dose-limiting Toxicity (DLT)</title>
        <description>A DLT was defined as any of the following events: Any SAE considered by the investigator to be at least reasonably or possibly related to study drug; Any Grade 3 clinical AE considered by the investigator to be at least reasonably or possibly related to study drug; Any Grade 3 confirmed laboratory abnormalities considered by the investigator to be at least reasonably or possibly related to study drug, except for asymptomatic Grade ¾ cholesterol and triglyceride; Any clinical or laboratory AE of any intensity that is considered by the investigator to be at least reasonably or possibly related to study drug that necessitates permanent discontinuation of study drug; Confirmed increase in QT interval corrected for heart rate using Fridericia's (QTcF) formula ≥60 msec over Baseline or an absolute QTcF ≥500 msec.</description>
        <time_frame>Up to 13 days</time_frame>
        <population>Safety Population: all participants who received at least one dose of the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Placebo (Cohort 1a-Cohort 5a - Pooled)</title>
            <description>Participants were administered a single dose of uprifosbuvir-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a) (Fasted and Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O6">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Group A: Placebo (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O13">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O14">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O15">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O16">
            <title>Groups C &amp; D: Uprifosbuvir 250 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 250 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O17">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O18">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O19">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O20">
            <title>Groups C &amp; D: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O21">
            <title>Groups C &amp; D: Placebo (Pooled)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O22">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O23">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O24">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O25">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced a Treatment-emergent Dose-limiting Toxicity (DLT)</title>
          <description>A DLT was defined as any of the following events: Any SAE considered by the investigator to be at least reasonably or possibly related to study drug; Any Grade 3 clinical AE considered by the investigator to be at least reasonably or possibly related to study drug; Any Grade 3 confirmed laboratory abnormalities considered by the investigator to be at least reasonably or possibly related to study drug, except for asymptomatic Grade ¾ cholesterol and triglyceride; Any clinical or laboratory AE of any intensity that is considered by the investigator to be at least reasonably or possibly related to study drug that necessitates permanent discontinuation of study drug; Confirmed increase in QT interval corrected for heart rate using Fridericia's (QTcF) formula ≥60 msec over Baseline or an absolute QTcF ≥500 msec.</description>
          <population>Safety Population: all participants who received at least one dose of the study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="10"/>
                <count group_id="O16" value="8"/>
                <count group_id="O17" value="18"/>
                <count group_id="O18" value="8"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="8"/>
                <count group_id="O21" value="9"/>
                <count group_id="O22" value="3"/>
                <count group_id="O23" value="3"/>
                <count group_id="O24" value="8"/>
                <count group_id="O25" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="0.0"/>
                    <measurement group_id="O14" value="0.0"/>
                    <measurement group_id="O15" value="0.0"/>
                    <measurement group_id="O16" value="0.0"/>
                    <measurement group_id="O17" value="0.0"/>
                    <measurement group_id="O18" value="0.0"/>
                    <measurement group_id="O19" value="0.0"/>
                    <measurement group_id="O20" value="0.0"/>
                    <measurement group_id="O21" value="0.0"/>
                    <measurement group_id="O22" value="0.0"/>
                    <measurement group_id="O23" value="0.0"/>
                    <measurement group_id="O24" value="0.0"/>
                    <measurement group_id="O25" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least One Treatment-emergent Grade 1, 2, 3, 4 or 5 Laboratory Abnormality</title>
        <description>Laboratory abnormalities were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Treatment-emergent AEs (TEAEs)were graded as: Grade 1: Mild TEAE as Worst Severity; Grade 2: Moderate TEAE as Worst Severity; Grade 3: Severe TEAE as Worst Severity; Grade 4: Potentially Life-Threatening TEAE as Worst Severity; Grade 5: TEAE Leading to Death. The percentage of participants who experienced at least one Grade 1, 2, 3, 4 or 5 laboratory abnormality is presented.</description>
        <time_frame>Up to 42 days</time_frame>
        <population>Safety Population: all participants who received at least one dose of the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Placebo (Cohort 1a-Cohort 5a - Pooled)</title>
            <description>Participants were administered a single dose of uprifosbuvir-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a) (Fasted and Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O6">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Group A: Placebo (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O13">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O14">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O15">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O16">
            <title>Groups C &amp; D: Uprifosbuvir 250 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 250 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O17">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O18">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O19">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O20">
            <title>Groups C &amp; D: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O21">
            <title>Groups C &amp; D: Placebo (Pooled)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O22">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O23">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O24">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O25">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least One Treatment-emergent Grade 1, 2, 3, 4 or 5 Laboratory Abnormality</title>
          <description>Laboratory abnormalities were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Treatment-emergent AEs (TEAEs)were graded as: Grade 1: Mild TEAE as Worst Severity; Grade 2: Moderate TEAE as Worst Severity; Grade 3: Severe TEAE as Worst Severity; Grade 4: Potentially Life-Threatening TEAE as Worst Severity; Grade 5: TEAE Leading to Death. The percentage of participants who experienced at least one Grade 1, 2, 3, 4 or 5 laboratory abnormality is presented.</description>
          <population>Safety Population: all participants who received at least one dose of the study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="10"/>
                <count group_id="O16" value="8"/>
                <count group_id="O17" value="18"/>
                <count group_id="O18" value="8"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="8"/>
                <count group_id="O21" value="9"/>
                <count group_id="O22" value="3"/>
                <count group_id="O23" value="3"/>
                <count group_id="O24" value="8"/>
                <count group_id="O25" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="66.7"/>
                    <measurement group_id="O11" value="33.3"/>
                    <measurement group_id="O12" value="66.7"/>
                    <measurement group_id="O13" value="66.7"/>
                    <measurement group_id="O14" value="45.5"/>
                    <measurement group_id="O15" value="60.0"/>
                    <measurement group_id="O16" value="37.5"/>
                    <measurement group_id="O17" value="33.3"/>
                    <measurement group_id="O18" value="0.0"/>
                    <measurement group_id="O19" value="37.5"/>
                    <measurement group_id="O20" value="25.0"/>
                    <measurement group_id="O21" value="33.3"/>
                    <measurement group_id="O22" value="0.0"/>
                    <measurement group_id="O23" value="100.0"/>
                    <measurement group_id="O24" value="12.5"/>
                    <measurement group_id="O25" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="33.3"/>
                    <measurement group_id="O14" value="18.2"/>
                    <measurement group_id="O15" value="0.0"/>
                    <measurement group_id="O16" value="50.0"/>
                    <measurement group_id="O17" value="5.6"/>
                    <measurement group_id="O18" value="62.5"/>
                    <measurement group_id="O19" value="37.5"/>
                    <measurement group_id="O20" value="25.0"/>
                    <measurement group_id="O21" value="33.3"/>
                    <measurement group_id="O22" value="0.0"/>
                    <measurement group_id="O23" value="0.0"/>
                    <measurement group_id="O24" value="37.5"/>
                    <measurement group_id="O25" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="33.3"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="0.0"/>
                    <measurement group_id="O14" value="9.1"/>
                    <measurement group_id="O15" value="10.0"/>
                    <measurement group_id="O16" value="0.0"/>
                    <measurement group_id="O17" value="5.6"/>
                    <measurement group_id="O18" value="0.0"/>
                    <measurement group_id="O19" value="0.0"/>
                    <measurement group_id="O20" value="0.0"/>
                    <measurement group_id="O21" value="0.0"/>
                    <measurement group_id="O22" value="0.0"/>
                    <measurement group_id="O23" value="0.0"/>
                    <measurement group_id="O24" value="12.5"/>
                    <measurement group_id="O25" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="0.0"/>
                    <measurement group_id="O14" value="0.0"/>
                    <measurement group_id="O15" value="0.0"/>
                    <measurement group_id="O16" value="0.0"/>
                    <measurement group_id="O17" value="0.0"/>
                    <measurement group_id="O18" value="0.0"/>
                    <measurement group_id="O19" value="0.0"/>
                    <measurement group_id="O20" value="12.5"/>
                    <measurement group_id="O21" value="0.0"/>
                    <measurement group_id="O22" value="0.0"/>
                    <measurement group_id="O23" value="0.0"/>
                    <measurement group_id="O24" value="0.0"/>
                    <measurement group_id="O25" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="0.0"/>
                    <measurement group_id="O14" value="0.0"/>
                    <measurement group_id="O15" value="0.0"/>
                    <measurement group_id="O16" value="0.0"/>
                    <measurement group_id="O17" value="0.0"/>
                    <measurement group_id="O18" value="0.0"/>
                    <measurement group_id="O19" value="0.0"/>
                    <measurement group_id="O20" value="0.0"/>
                    <measurement group_id="O21" value="0.0"/>
                    <measurement group_id="O22" value="0.0"/>
                    <measurement group_id="O23" value="0.0"/>
                    <measurement group_id="O24" value="0.0"/>
                    <measurement group_id="O25" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Drug Due to a Treatment-emergent AE</title>
        <description>The percentage of participants who discontinued study drug due to an AE is presented.</description>
        <time_frame>Up to 14 days</time_frame>
        <population>Safety Population: all participants who received at least one dose of the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Placebo (Cohort 1a-Cohort 5a - Pooled)</title>
            <description>Participants were administered a single dose of uprifosbuvir-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a) (Fasted and Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O6">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O8">
            <title>Group A: Placebo (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O9">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O10">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O11">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O12">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O13">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O14">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O15">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O16">
            <title>Groups C &amp; D: Uprifosbuvir 250 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 250 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O17">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O18">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O19">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O20">
            <title>Groups C &amp; D: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O21">
            <title>Groups C &amp; D: Placebo (Pooled)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O22">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O23">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O24">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O25">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Drug Due to a Treatment-emergent AE</title>
          <description>The percentage of participants who discontinued study drug due to an AE is presented.</description>
          <population>Safety Population: all participants who received at least one dose of the study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="10"/>
                <count group_id="O16" value="8"/>
                <count group_id="O17" value="18"/>
                <count group_id="O18" value="8"/>
                <count group_id="O19" value="8"/>
                <count group_id="O20" value="8"/>
                <count group_id="O21" value="9"/>
                <count group_id="O22" value="3"/>
                <count group_id="O23" value="3"/>
                <count group_id="O24" value="8"/>
                <count group_id="O25" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="0.0"/>
                    <measurement group_id="O14" value="0.0"/>
                    <measurement group_id="O15" value="0.0"/>
                    <measurement group_id="O16" value="0.0"/>
                    <measurement group_id="O17" value="0.0"/>
                    <measurement group_id="O18" value="0.0"/>
                    <measurement group_id="O19" value="0.0"/>
                    <measurement group_id="O20" value="0.0"/>
                    <measurement group_id="O21" value="0.0"/>
                    <measurement group_id="O22" value="0.0"/>
                    <measurement group_id="O23" value="0.0"/>
                    <measurement group_id="O24" value="0.0"/>
                    <measurement group_id="O25" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Drug Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>Pharmacokinetics (PK) Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Drug Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. All participants were fasted.</description>
          <population>Pharmacokinetics (PK) Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0410" spread="32.7"/>
                    <measurement group_id="O2" value="0.0837" spread="27.9"/>
                    <measurement group_id="O3" value="1.67" spread="62.7"/>
                    <measurement group_id="O4" value="2.78" spread="37.7"/>
                    <measurement group_id="O5" value="0.246" spread="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0640" spread="39.8"/>
                    <measurement group_id="O2" value="0.228" spread="49.1"/>
                    <measurement group_id="O3" value="0.341" spread="20.4"/>
                    <measurement group_id="O4" value="1.17" spread="NA">Not calculated</measurement>
                    <measurement group_id="O5" value="1.39" spread="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.394" spread="51.4"/>
                    <measurement group_id="O2" value="1.01" spread="52.9"/>
                    <measurement group_id="O3" value="2.80" spread="45.4"/>
                    <measurement group_id="O4" value="5.54" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.347" spread="36.2"/>
                    <measurement group_id="O2" value="0.935" spread="36.7"/>
                    <measurement group_id="O3" value="2.42" spread="46.8"/>
                    <measurement group_id="O4" value="4.59" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group C: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group C: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="51.7"/>
                    <measurement group_id="O2" value="3.11" spread="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="43.9"/>
                    <measurement group_id="O2" value="2.88" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="NA">Not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="32.8"/>
                    <measurement group_id="O2" value="4.21" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="31.8"/>
                    <measurement group_id="O2" value="3.51" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.39" spread="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum (Peak) Observed Plasma Drug Concentration (Cmax) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
        <description>Maximum observed plasma drug concentration was obtained. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum (Peak) Observed Plasma Drug Concentration (Cmax) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
          <description>Maximum observed plasma drug concentration was obtained. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="45.3"/>
                    <measurement group_id="O2" value="47.7" spread="54.4"/>
                    <measurement group_id="O3" value="1120" spread="47.8"/>
                    <measurement group_id="O4" value="1530" spread="53.6"/>
                    <measurement group_id="O5" value="119" spread="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293" spread="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2300" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2320" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="60.7"/>
                    <measurement group_id="O2" value="122" spread="26.4"/>
                    <measurement group_id="O3" value="168" spread="11.4"/>
                    <measurement group_id="O4" value="510" spread="NA">Not calculated</measurement>
                    <measurement group_id="O5" value="667" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
        <description>Maximum observed plasma drug concentration was obtained. All participants were fasted.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
          <description>Maximum observed plasma drug concentration was obtained. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286" spread="77.1"/>
                    <measurement group_id="O2" value="524" spread="80.1"/>
                    <measurement group_id="O3" value="1360" spread="55.5"/>
                    <measurement group_id="O4" value="2320" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" spread="45.6"/>
                    <measurement group_id="O2" value="587" spread="34.9"/>
                    <measurement group_id="O3" value="1200" spread="59.4"/>
                    <measurement group_id="O4" value="2490" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group C: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group C: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="618" spread="45.2"/>
                    <measurement group_id="O2" value="778" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537" spread="56.4"/>
                    <measurement group_id="O2" value="717" spread="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="613" spread="NA">Not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1440" spread="35.9"/>
                    <measurement group_id="O2" value="1090" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1550" spread="47.5"/>
                    <measurement group_id="O2" value="929" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2140" spread="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1910" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
        <description>Time to maximum plasma concentration was obtained. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
          <description>Time to maximum plasma concentration was obtained. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="32.7" lower_limit="0.50" upper_limit="1.05"/>
                    <measurement group_id="O2" value="1.00" spread="27.9" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O3" value="0.76" spread="62.7" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O4" value="0.50" spread="37.7" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O5" value="1.00" spread="63.2" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="47.8" lower_limit="3.00" upper_limit="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="26.6" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="19.9" lower_limit="0.50" upper_limit="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="39.8" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" spread="49.1" lower_limit="0.53" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" spread="20.4" lower_limit="0.68" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.76" spread="NA" lower_limit="0.52" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.00" spread="35.4" lower_limit="0.50" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="51.4" lower_limit="0.50" upper_limit="2.03"/>
                    <measurement group_id="O2" value="0.50" spread="52.9" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.00" spread="45.4" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O4" value="0.50" spread="40.1" lower_limit="0.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="36.2" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.50" spread="36.7" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.50" spread="46.8" lower_limit="0.48" upper_limit="3.00"/>
                    <measurement group_id="O4" value="0.50" spread="22.1" lower_limit="0.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group C: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group C: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="51.7" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.00" spread="45.0" lower_limit="0.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="43.9" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O2" value="0.50" spread="30.4" lower_limit="0.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir After Singe Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir After Singe Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="NA" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
        <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
          <description>AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="32.8" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O2" value="1.00" spread="35.2" lower_limit="0.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="31.8" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" spread="23.2" lower_limit="0.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, With Itraconazole (Group F)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, With Itraconazole (Group F)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="44.0" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="46.1" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Terminal Half-Life (t1/2) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Terminal Half-Life (t1/2) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.839" spread="27.3"/>
                    <measurement group_id="O2" value="0.872" spread="33.7"/>
                    <measurement group_id="O3" value="1.05" spread="25.0"/>
                    <measurement group_id="O4" value="1.13" spread="31.6"/>
                    <measurement group_id="O5" value="0.979" spread="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="52.7"/>
                    <measurement group_id="O2" value="0.926" spread="34.5"/>
                    <measurement group_id="O3" value="1.09" spread="32.5"/>
                    <measurement group_id="O4" value="1.11" spread="NA">Not calculated</measurement>
                    <measurement group_id="O5" value="1.59" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="25.1"/>
                    <measurement group_id="O2" value="1.11" spread="22.5"/>
                    <measurement group_id="O3" value="154." spread="34.0"/>
                    <measurement group_id="O4" value="2.58" spread="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group C: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group C: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="55.9"/>
                    <measurement group_id="O2" value="3.64" spread="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="NA">Not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="27.2"/>
                    <measurement group_id="O2" value="2.38" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, With Itraconazole (Group F)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, With Itraconazole (Group F)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
        <description>Area under the drug concentration-time curve from time zero to infinity for M6, a metabolite of uprifosbuvir, estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
          <description>Area under the drug concentration-time curve from time zero to infinity for M6, a metabolite of uprifosbuvir, estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="47.4"/>
                    <measurement group_id="O2" value="5.01" spread="27.2"/>
                    <measurement group_id="O3" value="19.8" spread="12.7"/>
                    <measurement group_id="O4" value="29.7" spread="32.1"/>
                    <measurement group_id="O5" value="8.77" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
        <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
          <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
        <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
          <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
        <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
          <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="22.3"/>
                    <measurement group_id="O2" value="5.78" spread="4.7"/>
                    <measurement group_id="O3" value="7.31" spread="11.1"/>
                    <measurement group_id="O4" value="17.5" spread="NA">Not calculated</measurement>
                    <measurement group_id="O5" value="33.4" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
        <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
          <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="37.6"/>
                    <measurement group_id="O2" value="8.94" spread="20.2"/>
                    <measurement group_id="O3" value="14.4" spread="20.8"/>
                    <measurement group_id="O4" value="19.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.12" spread="37.6"/>
                    <measurement group_id="O2" value="12.2" spread="18.9"/>
                    <measurement group_id="O3" value="19.0" spread="16.3"/>
                    <measurement group_id="O4" value="24.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
        <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group C: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group C: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
          <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="36.6"/>
                    <measurement group_id="O2" value="16.1" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="26.7"/>
                    <measurement group_id="O2" value="24.7" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
        <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
          <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="NA">Not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
        <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
          <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="22.3"/>
                    <measurement group_id="O2" value="18.4" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="23.5"/>
                    <measurement group_id="O2" value="26.1" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
        <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
          <description>Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>h*umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
        <description>Maximum observed plasma drug concentration was obtained. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
          <description>Maximum observed plasma drug concentration was obtained. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" spread="19.8"/>
                    <measurement group_id="O2" value="146" spread="13.6"/>
                    <measurement group_id="O3" value="758" spread="28.2"/>
                    <measurement group_id="O4" value="1190" spread="16.6"/>
                    <measurement group_id="O5" value="283" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1310" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1630" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="15.0"/>
                    <measurement group_id="O2" value="170" spread="7.2"/>
                    <measurement group_id="O3" value="279" spread="5.2"/>
                    <measurement group_id="O4" value="710" spread="NA">Not calculated</measurement>
                    <measurement group_id="O5" value="1210" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="34.2"/>
                    <measurement group_id="O2" value="641" spread="7.6"/>
                    <measurement group_id="O3" value="1130" spread="22.7"/>
                    <measurement group_id="O4" value="1560" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471" spread="33.7"/>
                    <measurement group_id="O2" value="931" spread="14.4"/>
                    <measurement group_id="O3" value="1420" spread="15.3"/>
                    <measurement group_id="O4" value="1760" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group C: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group C: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1010" spread="31.5"/>
                    <measurement group_id="O2" value="1210" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1420" spread="23.2"/>
                    <measurement group_id="O2" value="1680" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="597" spread="NA">Not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100" spread="11.5"/>
                    <measurement group_id="O2" value="1180" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1550" spread="11.4"/>
                    <measurement group_id="O2" value="1740" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
        <description>Maximum observed plasma drug concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
          <description>Maximum observed plasma drug concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="738" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1180" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
        <description>Time to maximum plasma concentration was obtained. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
          <description>Time to maximum plasma concentration was obtained. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" spread="32.7" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.50" spread="27.9" lower_limit="2.00" upper_limit="4.05"/>
                    <measurement group_id="O3" value="2.53" spread="62.7" lower_limit="2.00" upper_limit="6.05"/>
                    <measurement group_id="O4" value="3.50" spread="37.7" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O5" value="4.00" spread="63.2" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="48.5" lower_limit="6.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="3.77" lower_limit="2.00" upper_limit="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="21.7" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="39.8" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" spread="49.1" lower_limit="3.03" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.05" spread="20.4" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="3.52" spread="NA" lower_limit="3.03" upper_limit="4.00"/>
                    <measurement group_id="O5" value="4.00" spread="35.4" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="51.4" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="3.00" spread="52.9" lower_limit="0.98" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.00" spread="45.4" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.00" spread="40.1" lower_limit="3.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="36.2" lower_limit="1.92" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2.00" spread="36.7" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="3.00" spread="46.8" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="4.00" spread="22.1" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group C: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group C: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="51.7" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" spread="45.0" lower_limit="3.00" upper_limit="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="43.9" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.00" spread="30.4" lower_limit="3.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="NA" lower_limit="4.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1,HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1,HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="32.8" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.00" spread="35.2" lower_limit="3.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="31.8" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.00" spread="23.2" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
        <description>Time to maximum plasma concentration was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
          <description>Time to maximum plasma concentration was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="44.0" lower_limit="6.00" upper_limit="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="46.1" lower_limit="3.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="6.2"/>
                    <measurement group_id="O2" value="24.6" spread="12.8"/>
                    <measurement group_id="O3" value="29.1" spread="15.5"/>
                    <measurement group_id="O4" value="28.8" spread="14.2"/>
                    <measurement group_id="O5" value="22.9" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fed)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="3.4"/>
                    <measurement group_id="O2" value="21.2" spread="4.8"/>
                    <measurement group_id="O3" value="21.7" spread="19.8"/>
                    <measurement group_id="O4" value="26.9" spread="NA">Not calculated</measurement>
                    <measurement group_id="O5" value="28.0" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="16.8"/>
                    <measurement group_id="O2" value="28.9" spread="15.2"/>
                    <measurement group_id="O3" value="32.6" spread="12.7"/>
                    <measurement group_id="O4" value="35.8" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group C: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group C: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="7.7"/>
                    <measurement group_id="O2" value="30.8" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="NA">Not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="9.3"/>
                    <measurement group_id="O2" value="26.2" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
        <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
        <time_frame>Days 1 &amp; 7: predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)</title>
          <description>The time measured for the plasma concentration to decrease by one half (t1/2) was obtained.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Urine Excretion of Unchanged Uprifosbuvir in Healthy Participants (Group A)</title>
        <description>Cumulative urine excretion of unchanged MK-3682 in healthy participants was obtained. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Urine Excretion of Unchanged Uprifosbuvir in Healthy Participants (Group A)</title>
          <description>Cumulative urine excretion of unchanged MK-3682 in healthy participants was obtained. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>umol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.280" spread="0.0800"/>
                    <measurement group_id="O2" value="0.586" spread="0.164"/>
                    <measurement group_id="O3" value="7.73" spread="4.67"/>
                    <measurement group_id="O4" value="13.1" spread="4.16"/>
                    <measurement group_id="O5" value="1.56" spread="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Urine Excretion of Unchanged M6 in Healthy Participants (Group A)</title>
        <description>Cumulative urine excretion of unchanged M6 in healthy participants was obtained. All participants were fasted.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours postdose</time_frame>
        <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Uprifosbuvir 150 mg (Cohort 4a Fasted)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
            <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Urine Excretion of Unchanged M6 in Healthy Participants (Group A)</title>
          <description>Cumulative urine excretion of unchanged M6 in healthy participants was obtained. All participants were fasted.</description>
          <population>PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to uprifosbuvir who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).</population>
          <units>umol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="1.42"/>
                    <measurement group_id="O2" value="15.2" spread="2.50"/>
                    <measurement group_id="O3" value="101" spread="6.86"/>
                    <measurement group_id="O4" value="200" spread="37.9"/>
                    <measurement group_id="O5" value="31.8" spread="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reduction in HCV RNA From Baseline on Day 8 Following Uprifosbuvir 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
        <description>Reduction in HCV RNA from baseline on Day 8 following uprifosbuvir 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-infected participants was obtained.</description>
        <time_frame>Baseline and Day 8</time_frame>
        <population>Per-Protocol Population: participants who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Groups C &amp; D: Placebo (Pooled)</title>
            <description>Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Groups C &amp; D: Uprifosbuvir 300 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Groups C &amp; D: Uprifosbuvir 450 mg (Tablet)</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in HCV RNA From Baseline on Day 8 Following Uprifosbuvir 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)</title>
          <description>Reduction in HCV RNA from baseline on Day 8 following uprifosbuvir 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-infected participants was obtained.</description>
          <population>Per-Protocol Population: participants who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" spread="0.879" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="6.00" spread="0.630" lower_limit="0.98" upper_limit="4.00"/>
                    <measurement group_id="O3" value="6.16" spread="0.633" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="6.11" spread="0.540" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="6.27" spread="0.485"/>
                    <measurement group_id="O6" value="5.92" spread="0.838"/>
                    <measurement group_id="O7" value="5.97" spread="0.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.440"/>
                    <measurement group_id="O2" value="2.49" spread="0.733"/>
                    <measurement group_id="O3" value="4.22" spread="0.614"/>
                    <measurement group_id="O4" value="4.39" spread="0.433"/>
                    <measurement group_id="O5" value="0.42" spread="0.229"/>
                    <measurement group_id="O6" value="3.34" spread="0.643"/>
                    <measurement group_id="O7" value="4.50" spread="0.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Reduction in log10 HCV RNA From Baseline - Normal Participants (From Groups B and C) vs. Mild Hepatic Impairment Participants (Group E)</title>
        <description>Reduction in HCV RNA from baseline on Day 8 following uprifosbuvir 50-450 mg for 7 Days in Genotype (Gt) 1, HCV-infected participants was obtained.</description>
        <time_frame>Baseline and 28 days after last dose of study drug (Up to 42 days)</time_frame>
        <population>Per-Protocol Population: participants who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
            <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Group C: Uprifosbuvir 300 mg (Capsule)</title>
            <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Group E: Uprifosbuvir 450 mg</title>
            <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Reduction in log10 HCV RNA From Baseline - Normal Participants (From Groups B and C) vs. Mild Hepatic Impairment Participants (Group E)</title>
          <description>Reduction in HCV RNA from baseline on Day 8 following uprifosbuvir 50-450 mg for 7 Days in Genotype (Gt) 1, HCV-infected participants was obtained.</description>
          <population>Per-Protocol Population: participants who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.91" spread="0.347"/>
                    <measurement group_id="O2" value="6.16" spread="0.633"/>
                    <measurement group_id="O3" value="6.14" spread="0.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal hepatic fcn: Gt1a</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="NA"/>
                    <measurement group_id="O2" value="4.82" spread="0.504"/>
                    <measurement group_id="O3" value="5.06" spread="0.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild hepatic impairment: Gt1a</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.92" spread="0.239"/>
                    <measurement group_id="O3" value="3.60" spread="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal hepatic fcn: Gt1b</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="NA"/>
                    <measurement group_id="O2" value="3.82" spread="0.636"/>
                    <measurement group_id="O3" value="4.28" spread="0.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild hepatic impairment: Gt1b</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.774"/>
                    <measurement group_id="O2" value="3.59" spread="NA"/>
                    <measurement group_id="O3" value="3.08" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal hepatic fcn: Gt1 (pooled 1a+1b)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.274"/>
                    <measurement group_id="O2" value="4.19" spread="0.754"/>
                    <measurement group_id="O3" value="4.50" spread="0.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild hepatic impairment;Gt1 (pooled 1a+1b)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.774"/>
                    <measurement group_id="O2" value="3.15" spread="0.420"/>
                    <measurement group_id="O3" value="3.16" spread="0.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 42 days (28 days after last study drug administration)</time_frame>
      <desc>Safety Population: participants who received at least one dose of the study drug. For Cohort 4a, serious AEs and nonserious AEs are presented for participants on the fasted regimen.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A: Placebo (Cohort 1a - Cohort 5a - Pooled)</title>
          <description>Participants were administered a single dose of uprifosbuvir-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).</description>
        </group>
        <group group_id="E2">
          <title>Group A: Uprifosbuvir 10 mg (Cohort 1a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E3">
          <title>Group A: Uprifosbuvir 25 mg (Cohort 2a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E4">
          <title>Group A: Uprifosbuvir 50 mg (Cohort 3a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E5">
          <title>Group A: Uprifosbuvir 150 mg (Cohort 4a)</title>
          <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.</description>
        </group>
        <group group_id="E6">
          <title>Group A: Uprifosbuvir 300 mg (Cohort 5a)</title>
          <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E7">
          <title>Group A: Placebo (Cohort 6a)</title>
          <description>Participants were administered single doses of uprifosbuvir-matching placebo oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E8">
          <title>Group A: Uprifosbuvir 300 mg (Cohort 6a)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E9">
          <title>Group B: Uprifosbuvir 10 mg (Cohort 1b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 10 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E10">
          <title>Group B: Uprifosbuvir 25 mg (Cohort 2b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 25 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E11">
          <title>Group B: Uprifosbuvir 50 mg (Cohort 3b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 50 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E12">
          <title>Group B: Uprifosbuvir 150 mg (Cohort 4b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E13">
          <title>Group B: Uprifosbuvir 300 mg (Cohort 5b)</title>
          <description>Participants were administered a single dose of uprifosbuvir 300 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E14">
          <title>Groups C &amp; D: Uprifosbuvir 50 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 50 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E15">
          <title>Groups C &amp; D: Uprifosbuvir 150 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 150 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E16">
          <title>Groups C &amp; D: Uprifosbuvir 250 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 250 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E17">
          <title>Groups C &amp; D: Uprifosbuvir 300 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E18">
          <title>Groups C &amp; D: Uprifosbuvir 400 mg (Capsule)</title>
          <description>Participants were administered single doses of uprifosbuvir 400 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E19">
          <title>Groups C &amp; D: Uprifosbuvir 300 mg (Tablet)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E20">
          <title>Groups C &amp; D: Uprifosbuvir 450 mg (Tablet)</title>
          <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E21">
          <title>Groups C &amp; D: Placebo (Pooled)</title>
          <description>Participants were administered single doses of uprifosbuvir-matching placebo as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E22">
          <title>Group E: Uprifosbuvir 150 mg (Cohort 1e)</title>
          <description>Participants were administered a single dose of uprifosbuvir 150 mg as oral capsules under fasted conditions.</description>
        </group>
        <group group_id="E23">
          <title>Group E: Uprifosbuvir 300 mg (Cohort 2e)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral capsules once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E24">
          <title>Group E: Uprifosbuvir 450 mg (Cohort 3e)</title>
          <description>Participants were administered single doses of uprifosbuvir 450 mg as oral tablets once daily for 7 days under fasted conditions.</description>
        </group>
        <group group_id="E25">
          <title>Group F: Uprifosbuvir 300 mg (Tablet)</title>
          <description>Participants were administered single doses of uprifosbuvir 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E19" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E20" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E21" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E24" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E25" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site anaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vessel puncture site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E17" events="4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E18" events="5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E19" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E25" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Menstruation delayed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin odour abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution and Investigator will submit any proposed publication to Sponsor for review and comment at least sixty (60) days prior to submission to a third party. If Sponsor believes in good faith that any proposed publication contains any proprietary or confidential information, Sponsor shall have the right to remove such references to such confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

